Showing posts with label Topomax. Show all posts
Showing posts with label Topomax. Show all posts

Monday, November 21, 2011

Sphenopalatine Ganglion Implicated in Migraines and Cluster Headaches via Cerebrovascular Autonomic Physiology

The pathophysiology or cause of almost all headaches, migraines, cluster headaches and tension-type headache involve the Trigeminal Nerve which can effectively be treated in mane headache sufferers through neuromuscular dentistry. Another pathway of relieving chronic headache pain is by utilizing a SPG or Sphenopalatine Ganglion Block which affects the autonomic nervous system and is readily accessible to dentists with either palatal injection or nasal swab.

Newer techniques involving neurostimulation hold promise but the simple use of lidocaine on a nasal swab often produces miraculous relief for patients. When combined with a diagnostic neuromuscular orthotic a 50 - 80% success rate easily achieved in most patients. The following PubMed abstract discusses possible new avenues of addressing the sphenopalatine ganglion. I would advise patients to start with nasal or palatal block. Nasal blocks are easily learned by patients for home administration and can be used to prophylactically to abort migraines similar to triptans or topomax with fewer side effects.
Prog Neurol Surg. 2011;24:171-9. Epub 2011 Mar 21.

Sphenopalatine ganglion interventions: technical aspects and application.

Source

Department of Neurological Surgery, Ohio State University Medical Center, Columbus, Ohio 43210, USA.

Abstract

Recent research has highlighted the important role of the sphenopalatine ganglion (SPG) in cerebrovascular autonomic physiology and in the pathophysiology of cluster and migraine headaches as well as conditions of stroke and cerebral vasospasm. The relatively accessible location of the SPG within the pterygopalatine fossa and the development of options for minimally invasive approaches to the SPG make it an attractive target for neuromodulation approaches. The obvious advantage of SPG stimulation compared to ablative procedures on the SPG such as radiofrequency destruction and stereotactic radiosurgery is its reversibility and adjustable features. The on-going design of strategies for transient and continuous SPG stimulation on as needed basis using implantable SPG stimulators is an exciting new development which is expected to expand the clinical versatility of this technique.

Copyright © 2011 S. Karger AG, Basel.

PMID:
21422787
[PubMed - in process]

Sunday, October 30, 2011

Accupuncture vs Topiramate: New Study in October Cephalgi ( Oct 21, 2011)Shows Superior Results With Accupunture

Neuromuscular Dentistry and accupuncture bot work by restoring normal physiologic states to the body compared to drug treatments that can destroy chemical balance. The current study shows accupuncture to be superior to topiramate but of greater importance is the frequency of side effects. (abstract below)

I will state that Neuromuscular Diagnostic orthotics almost always give better results than either therapy. I frequently work with patients on extremely high levels of medication that is gradually reduced by their physician following treatment. One of the most difficult issues in treating headache patients is medication withdrawal.

Topiramate had adverse events or side effects in 66% of patients compared to 6% in accupuncture group. This level of side effects for drug therapy is enormous considering it did not work as well as accupunture.

The reduction in headaches days was significantly greater with accupuncture.

Cephalalgia. 2011 Oct 21. [Epub ahead of print]

Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial.

Source

Kuang Tien General Hospital and Chang Gung University, Taiwan.

Abstract

Background: The aim of this study was to investigate the efficacy and tolerability of acupuncture compared with topiramate treatment in chronic migraine (CM) prophylaxis. Methods: A total of 66 consecutive and prospective CM patients were randomly divided into two treatment arms: 1) acupuncture group: acupuncture administered in 24 sessions over 12 weeks (n = 33); and 2) topiramate group: a 4-week titration, initiated at 25 mg/day and increased by 25 mg/day weekly to a maximum of 100 mg/day followed by an 8-week maintenance period (n = 33). Results: A significantly larger decrease in the mean monthly number of moderate/severe headache days (primary end point) from 20.2 ± 1.5 days to 9.8 ± 2.8 days was observed in the acupuncture group compared with 19.8 ± 1.7 days to 12.0 ± 4.1 days in the topiramate group (p < .01) Significant differences favoring acupuncture were also observed for all secondary efficacy variables. These significant differences still existed when we focused on those patients who were overusing acute medication. Adverse events occurred in 6% of acupuncture group and 66% of topiramate group. Conclusion: We suggest that acupuncture could be considered a treatment option for CM patients willing to undergo this prophylactic treatment, even for those patients with medication overuse.

PMID:
22019576
[PubMed - as supplied by publisher]

Thursday, January 14, 2010

21 year old frequent headaches and migraine with no relief.

A recent email brings up many interesting questions. My comments follow this distressing case.

"I am writing this on behalf of our 21 year old son who has dealt with frequent headaches since kindergarten. The headaches have gotten more frequent and more severe as the years have gone by. Currently, he averages 4-5 headaches a week and approximately 2 migraines a month.
He takes Extra Strength Excedrin at the first sign of a headache. If there is no relief within 30 minutes, he will take a Relpax. We have tried food diaries, monitoring sleep patterns, massage therapy, chiropractors, and even sought 3 surgeons asking if his non-union clavicle could possible be the source of his headaches. He has tried Topomax, but no longer takes it daily.
He has had orthodontic work done and now wears a retainer nightly. Only recently have we thought to consider sleep apnea (he has always been a very restless sleeper; i.e. tossing and turning) and possibly TMJ. He is seeing a dentist tomorrow (1/14) and will ask about the TMJ.
Is it possible that this could be the cause of his headaches? I know my son would be thrilled if he could just have one headache a month! Even if it were a migraine, it would be better than what he is dealing with currently.
Thank you for your time, and I apologize if this is the second email you have received from me. I am sending this from work and because I have not heard from you, I am not sure you received my previous post."

Reply
This case brings up many interesting questions. When do the headaches occur? Does the patient wake in the morning with headaches or does pain wake him from sleep. Patients that only occur in the morning can sometimes be treated with a nightime only appliance but sleep apnea must be ruled out as a causes. The most common causes of morning headaches are sleep apnea and TMD (includes bruxism and clenching) TMD does not always have pain or clicking in the joint.

A second question is how much extra strength Excedrin (and caffeine) A patient can have a medication rebound headache as well. Orthodontics can make headaches, sleep apnea and TMJ problems better or worse or have no effect. If the ortho pulled the jaw back it is likely to make the problem worse. Also, was there bicuspids removed to treat the case? Removal of teeth, in my experience usually will make sleep apnea worse.

As discussed in previous posts Sleep Apnea is a TMJ disorder and I strongly Rx anyone with morning headaches, migraines or TMJ disorders read the NHLBI (National Heart Lng and Blood Institue) article "CARDIOVASCULAR AND SLEEP-RELATED
CONSEQUENCES OF TEMPOROMANDIBULAR DISORDERS" http://www.nhlbi.nih.gov/meetings/workshops/tmj_wksp.pdf

The following is excerpted from the NHLBI paper:

"Mandibular Movements, Upper Airway Resistance, Breathing and Swallowing
There appears to an associated increase in coughing in subjects with sleep apnea. Occlusion of
the pharynx can force residual secretions into the glottis and trigger coughing reflexes,
swallowing reflexes, and other reflexes that could contribute to the disorganization of breathing
during sleep. In addition to the muscles of mastication, the tongue plays an important role in
the coordinated events of swallowing and breathing. The integration of breathing and
swallowing is tightly linked, and these events in turn are in some manner linked to blood
pressure regulation. Each of these pathways has been studied by scientists in individual
disciplines, but there is a need for interdisciplinary studies to determine the interactions of the
peripheral and central neural pathways controlling breathing, chewing, swallowing, and
cardiovascular events. The presence of pain in patients with TMD would be expected to
seriously impact upon these reflex and motor pathways. Little is known about the role of tongue
position and how this may be altered in subjects with altered jaw location and structure. Sleep
state has been shown to alter the central modulation of the coordination of breathing, airway
dynamics, swallowing, and associated cardiovascular events. Differences in central modulation
of these events in subjects with sleep apnea and TMD need to be evaluated using sleep as a
dynamic change in the state of the individual."

The paper also suggests 60-90% resolution which frequently occurs in treatment. I believe that Neuromuscular Dental treatment increases that success rate considerably.

Neuromuscular Dentistry has been shown to be "overwhelmingly successful according to Dr Barry Cooper's research reported in Cranio. The PubMED abstracts are include at the bottom of the post for convenience.

Other questions include what were the effects of physical medicine such as Chiropractic and massage and were the treatment combined. Was there no relief or only temporary relief. When either of those therapies only gives temporary relief you should suspect a problem with the neuromuscular bite position. TMD is a repetitive strain condition and breathing and swallowing as well as postural conditions can effect the bite just as the jaw position effects the entire bodies balance. The strongest influence on headaches is thru the trigeminal nerve.

An excellent way to both diagnose a cause and effect of jaw muscles to headache pain is the use of trigger point injections and diagnostic blocks. Frequently a severe headache can be relieved by judicious use of TP injections. Recurrent headaches are usually less frequent and severe if successful.

Cranio. 2009 Apr;27(2):101-8.
Relationship of temporomandibular disorders to muscle tension-type headaches and a neuromuscular orthosis approach to treatment.
Cooper BC, Kleinberg I.

Department of Oral Biology and Pathology of the State University of New York (SUNY) Stony Brook School of Dental Medicine, NY, USA. tmjbcooper@aol.com
A prominent etiological theory proposed for TMD related headache is that it results from a dysfunctional masticatory muscle system, wherein muscle hyperactivity is frequently caused by dental temporomandibular disharmony. The central goal of this article was to determine from a literature review of the subject whether there is significant evidence to support a relationship between headaches and TMD prevalence. A second purpose was to determine from such a review whether any relationship was one of cause and effect and whether treatment of the TMD condition can result in meaningful reduction or resolution of headaches. In the literature, there was a substantial amount of evidence for a positive relationship between TMD and the prevalence of headaches, and most importantly, that these were the muscle tension-type. Evidence for a cause and effect relationship was strong. It generally showed in numerous patients that TMD treatment of a large number of patients resulted in significant improvement in the physiological state of the masticatory system (muscles, joints and dental occlusion). Reduction or resolution of muscle tension-type headaches that were present was clinically significant. The authors concluded that TMD should be considered and explored as a possible causative factor when attempts are made to determine and resolve the cause of headaches in patients with this affliction. A benefit of resolving headaches at an early stage in their development is that it might result in the reduction of its potential for progression to a chronic and possibly migraine headache condition.

Cranio. 2008 Apr;26(2):104-17.
Establishment of a temporomandibular physiological state with neuromuscular orthosis treatment affects reduction of TMD symptoms in 313 patients.
Cooper BC, Kleinberg I.

Department of Oral Biology and Pathology, State University of New York (SUNY) Stony Brook School of Dental Medicine, USA. tmjbcooper@aol.com
Comment in:

Cranio. 2008 Jul;26(3):166; author reply 167.
The objective of this investigation was to test the hypothesis that alteration of the occlusions of patients suffering from temporomandibular disorders (TMD) to one that is neuromuscularly, rather than anatomically based, would result in reduction or resolution of symptoms that characterize the TMD condition. This hypothesis was proven correct in the present study, where 313 patients with TMD symptoms were examined for neuromuscular dysfunction, using several electronic instruments before and after treatment intervention. Such instrumentation enabled electromyographic (EMG) measurement of the activities of the masticatory muscles during rest and in function, tracking and assessment of various movements of the mandible, and listening for noises made by the TMJ during movement of the mandible. Ultra low frequency and low amplitude, transcutaneous electrical neural stimulation (TENS) of the mandibular division of the trigeminal nerve (V) was used to relax the masticatory muscles and to facilitate location of a physiological rest position for the mandible. TENS also made it possible to select positions of the mandible that were most relaxed above and anterior to the rest position when the mandible was moved in an arc that began at rest position. Once identified, the neuromuscular occlusal position was recorded in the form of a bite registration, which was subsequently used to fabricate a removable mandibular orthotic appliance that could be worn continuously by the patient. Such a device facilitated retention and stabilization of the mandible in its new-found physiological position, which was confirmed by follow up testing. Three months of full-time appliance usage showed that the new therapeutic positions achieved remained intact and were associated with improved resting and functioning activities of the masticatory muscles. Patients reported overwhelming symptom relief, including reduction of headaches and other pain symptoms. Experts consider relief of symptoms as the gold standard for assessment of effectiveness of TMD treatment. It is evident that this outcome has been achieved in this study and that taking patients from a less to a more physiological state is an effective means for reducing or eliminating TMD symptoms, especially those related to pain, most notably, headaches.

PMID: 18468270 [PubMed - indexed for MEDLINE]

Thursday, December 31, 2009

Headaches and Chiari Malformation

Headaches and Chiari Malformation

comments : I am 25 years old and am suffering from headaches. I have had a headache every second of every day for the past 11 months. I saw a neurosurgeon who diagnosed me with a small Chiari Malformation that was constricting the flow of my spinal fluid. He performed a decompression surgery with the hope that my headaches would be relieved. It has been almost 8 months since the surgery, and I have found no relief. He prescribed me a couple of different narcotics, but I experienced no pain relief.He had me make an appointment with a headache specialist whom I will not be able to see for another month. I have, however, been seeing a Nurse Practitioner in the neurologist's office who has placed me on several tryptan medications (I have tried four so far). I was placed on Topamax, but it had no effect, and I developed kidney stones (a known side effect). She also had me take muscle relaxers for a month to see if they would have an effect on the pain, but they did not. I am curre
ntly on Keppra (500 mg a day). I have only been on it two weeks, and the severity of my headaches has increased. I have ocular symptoms as well, shadows and spots in my field of vision, which an opthamalogist believes are a result of the headache. Since I was 11 years old, I have had difficulties with my left temporomandibular joint. I have pain if I open my mouth to far, as well as the common popping and scraping soulnds. My jaw has become increasingly stiff over the past several months. The constant pain is wearing me down and making it difficult to concentrate in school as well as perform my job at a daycare due to my sensitivity to sound. I do not know if there is any type of advice or information you can offer me, but I would appreciate your consideration. HEATHER

Dear Heather
While they found the Chiari malformation because they investigated your headache symptoms that does not mean that it was the cause of your pain initially. It is relatively common to have an assymptomatic Chiari malformation. Because that did not help your headache pain it probably was not the cause of the pain but rather a accidental finding. The malformation was not new, only the severity of the pain was new.

The majority of headaches are related to problems or disturbances of the trigeminal nervous system. With your history of jaw problems and I would tell you to consider trying a DIAGNOSTIC Neuromuscular Orthotic. It is rare for patients not to have significant relief from an orthotic. That does not mean 100% relief. I tell my patients that we initially seek 50-80% relief and then seek 50-80% reduction in residual pain. I frequently get out of town patients who come to Chicago but I will be glad to work with your Neuromuscular Dentist to help you through this difficult time. Frequently trigger point injections and or SPG nerve blocks can be helpful in treating pain problems similar to yours.

I am leaving the country for the next couple of weeks but please feel free to contact me again.

Sunday, December 20, 2009

BOTOX VS TOPOMAX IN MIGRAINE TREATMENT

This study in Headache. 2009 Nov-Dec;49(10):1401 was evaluating effects of Botox (onabotulinumtoxinA) vs Topomax (topiramate) on 60 patients (90% female). The reports site that they have similar success however only 40-42% of patients had a 50% decrease in symptoms. 24% in the topiramate had adverse effects from the drugs compard to only 7% in the onabotulinumtoxinA group.

There were adverse reactions (AE) in 9 out of 60 patients. Only 36/60 even lasted the 9 months of the study. It reported
"Forty-one treatment-related AEs were reported in 18 onabotulinumtoxinA-treated patients vs 87 in 25 topiramate-treated patients, and 2.7% of patients in the onabotulinumtoxinA group and 24.1% of patients in the topiramate group reported AEs that required permanent discontinuation of study treatment. CONCLUSIONS: OnabotulinumtoxinA and topiramate demonstrated similar efficacy in the prophylactic treatment of CM. Patients receiving onabotulinumtoxinA had fewer AEs and discontinuations."

The Advantage of Neuromuscular dentistry is a high success rate (80-95% of patients exhibit substantial improvement) and adverse drug reactions are not a problem. This is a relatively short term study and does not address AE's from long term use.

While there is a place for these drugs in the treatment of migraines they definitely have limits of both safety and effectiveness.

An enormous plus with neuromuscular treatment is that significant reductions in Tension-Type headaches, Chronic daily headaches as well as migraine being reduce in frequency and severity. Many additional symptoms are also relieve simultaneously including ear pain, ear pressure, tinnitus or ring in the ear, sinus pain and/or pressure, retroorbital pain, pain and clicking ot the TM Joint (TMJ). TMD is often called The Great Imposter (http://www.sleepandhealth.com/story/suffer-no-more-dealing-great-impostor)

PubMed Abstract
A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
Mathew NT, Jaffri SF.

Houston Headache Clinic-Neurology, 1213 Herman Drive, Houston, TX 77004, USA.
Comment in:

Headache. 2009 Nov-Dec;49(10):1401.
BACKGROUND: There is a need for effective prophylactic therapy for chronic migraine (CM) that has minimal side effects. OBJECTIVE: To compare the efficacy and safety of onabotulinumtoxinA (BOTOX), Allergan, Inc., Irvine, CA) and topiramate (TOPAMAX), Ortho-McNeil, Titusville, NJ) prophylactic treatment in patients with CM. METHODS: In this single-center, double-blind trial, patients with CM received either onabotulinumtoxinA, maximum 200 units (U) at baseline and month 3 (100 U fixed-site and 100 U follow-the-pain), plus an oral placebo, or topiramate, 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections. OnabotulinumtoxinA or placebo saline injection was administered at baseline and month 3 only, while topiramate oral treatment or oral placebo was continued through the end of the study. The primary endpoint was treatment responder rate assessed using Physician Global Assessment 9-point scale (+4 = clearance of signs and symptoms and -4 = very marked worsening [about 100% worse]). Secondary endpoints included the change from baseline in the number of headache (HA)/migraine days per month (HA diary), and HA disability measured using Headache Impact Test (HIT-6), HA diary, Migraine Disability Assessment (MIDAS) questionnaire, and Migraine Impact Questionnaire (MIQ). The overall study duration was approximately 10.5 months, which included a 4-week screening period and a 2-week optional final safety visit. Follow-up visits for assessments occurred at months 1, 3, 6, and 9. Adverse events (AEs) were documented. RESULTS: Of 60 patients randomized to treatment (mean age, 36.8 +/- 10.3 years; 90% female), 36 completed the study at the end of the 9 months of active treatment (onabotulinumtoxinA, 19/30 [63.3%]; topiramate, 17/30 [56.7%]). In the topiramate group, 7/29 (24.1%) discontinued study because of treatment-related AEs vs 2/26 (7.7%) in the onabotulinumtoxinA group. Between 68% and 83% of patients for both onabotulinumtoxinA and topiramate groups reported at least a slight (25%) improvement in migraine; response to treatment was assessed using Physician Global Assessment at months 1, 3, 6, and 9. Most patients in both groups reported moderate to marked improvements at all time points. No significant between-group differences were observed, except for marked improvement at month 9 (onabotulinumtoxinA, 27.3% vs topiramate, 60.9%, P = .0234, chi-square). In both groups, HA/migraine days decreased and MIDAS and HIT-6 scores improved. Patient-reported quality of life measures assessed using MIQ after treatment with onabotulinumtoxinA paralleled those seen after treatment with topiramate in most respects. At month 9, 40.9% and 42.9% of patients in the onabotulinumtoxinA and topiramate groups, respectively, reported > or =50% reduction in HA/migraine days. Forty-one treatment-related AEs were reported in 18 onabotulinumtoxinA-treated patients vs 87 in 25 topiramate-treated patients, and 2.7% of patients in the onabotulinumtoxinA group and 24.1% of patients in the topiramate group reported AEs that required permanent discontinuation of study treatment. CONCLUSIONS: OnabotulinumtoxinA and topiramate demonstrated similar efficacy in the prophylactic treatment of CM. Patients receiving onabotulinumtoxinA had fewer AEs and discontinuations.

PMID: 19912346 [PubMed - in process]